Corcept’s stock up as relacorilant meets OS goal in Phase III ovarian cancer trial
Corcept Therapeutics’ stock has risen 14% after its selective cortisol modulator relacorilant met its overall survival (OS) goal in a …
Corcept Therapeutics’ stock has risen 14% after its selective cortisol modulator relacorilant met its overall survival (OS) goal in a …
The US is poised to leave the World Health Organization (WHO) as the one-year countdown of legal notice comes to …
According to the World Health Organization, approximately one in 127 individuals worldwide had autism spectrum disorder (ASD) in 2021. ASD …
Eczema, also known as dermatitis, is a skin condition characterised by dry, itchy, and inflamed skin. Its symptoms can impact …
Kardium has unveiled further results from the pivotal trial of its Globe Pulsed Field System, demonstrating the system’s success in …
Kardium has unveiled further results from the pivotal trial of its Globe Pulsed Field System, demonstrating the system’s success in …
Bio Behavioral Health (BBH) has entered a partnership with PhaseWell Research aimed at expanding access to neuropsychiatric clinical trials. The collaboration …
Worldwide Clinical Trials has entered a definitive agreement to acquire oncology contract research organisation (CRO) Catalyst Clinical Research. The transaction will …
Rare disease biotech Genespire is looking to take its single-dose gene therapy – GENE202 – to the clinic in 2026, …
IntraBio will head to regulators after its neurological rare disease drug met primary and secondary endpoints in a Phase III …
According to GlobalData, industry-sponsored trials have increased from 7,721 in 2016 to 13, 685 in 2025. This growth over the …
Vibrent Health is set to join a hybrid/remote decentralised clinical research study funded by the Biomedical Advanced Research and Development …
Lipocine has announced the completion of enrolment and participant dosing in its Phase III clinical trial investigating LPCN 1154, an …
A combination of Moderna and MSD's personalised cancer vaccine, intismeran autogene, and MSD’s stalwart oncology drug, Keytruda (pembrolizumab), has significantly …
Skin disease has a growing profile in drug development. New immuno-dermatology agents, topical biologics and cell-based treatments are moving through …